MX2019005651A - Metodos para tratar la obesidad con anticuerpos anti-angptl8. - Google Patents

Metodos para tratar la obesidad con anticuerpos anti-angptl8.

Info

Publication number
MX2019005651A
MX2019005651A MX2019005651A MX2019005651A MX2019005651A MX 2019005651 A MX2019005651 A MX 2019005651A MX 2019005651 A MX2019005651 A MX 2019005651A MX 2019005651 A MX2019005651 A MX 2019005651A MX 2019005651 A MX2019005651 A MX 2019005651A
Authority
MX
Mexico
Prior art keywords
methods
angptl8
treating obesity
antibodies
angptl8 antibodies
Prior art date
Application number
MX2019005651A
Other languages
English (en)
Inventor
J Murphy Andrew
Gusarova Viktoria
Gromada Jesper
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019005651A publication Critical patent/MX2019005651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a ANGPTL8 y métodos para usar los mismos. De acuerdo con ciertas modalidades, la invención incluye métodos de uso de anticuerpos anti-ANGPTL8 que se unen a ANGPTL8 humana con alta afinidad para tratar la obesidad, reducir la grasa corporal, reducir el peso corporal, aumentar el gasto de energía y aumentar el HDL-C, en un sujeto.
MX2019005651A 2016-11-17 2017-11-16 Metodos para tratar la obesidad con anticuerpos anti-angptl8. MX2019005651A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423639P 2016-11-17 2016-11-17
PCT/US2017/062103 WO2018094112A1 (en) 2016-11-17 2017-11-16 Methods of treating obesity with anti-angptl8 antibodies

Publications (1)

Publication Number Publication Date
MX2019005651A true MX2019005651A (es) 2019-11-12

Family

ID=60655071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005651A MX2019005651A (es) 2016-11-17 2017-11-16 Metodos para tratar la obesidad con anticuerpos anti-angptl8.

Country Status (13)

Country Link
US (1) US10442856B2 (es)
EP (1) EP3541839A1 (es)
JP (1) JP7133551B2 (es)
KR (1) KR20190078650A (es)
CN (1) CN110036029A (es)
AU (1) AU2017363143B2 (es)
CA (1) CA3044249A1 (es)
EA (1) EA201991203A1 (es)
IL (1) IL266564A (es)
MA (1) MA46842A (es)
MX (1) MX2019005651A (es)
WO (1) WO2018094112A1 (es)
ZA (1) ZA201902608B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054494A1 (en) 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN111315775A (zh) 2017-11-10 2020-06-19 恩格姆生物制药公司 Angptl8-结合剂及其使用方法
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
MX2022000726A (es) 2019-07-19 2022-02-10 Oncoresponse Inc Anticuerpos inmunomoduladores y metodos de uso de los mismos.
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111690058B (zh) * 2020-03-30 2021-02-05 三优生物医药(上海)有限公司 针对冠状病毒的具有中和活性的抗体及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20020132253A1 (en) 1997-06-16 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
KR100510795B1 (en) 1999-08-31 2005-08-30 Compositions and Methods for the Treatment of Tumor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
EA200901550A1 (ru) 2007-05-22 2010-10-29 Новартис Аг Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
EP2506861A1 (en) 2009-12-02 2012-10-10 Amgen Inc. Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
WO2016054494A1 (en) 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methods and compositions for treatment of conditions associated with elevated triglycerides
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
AU2017248356A1 (en) 2016-04-08 2018-10-25 Regeneron Pharmaceuticals, Inc. Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor

Also Published As

Publication number Publication date
US10442856B2 (en) 2019-10-15
AU2017363143A1 (en) 2019-05-23
EP3541839A1 (en) 2019-09-25
IL266564A (en) 2019-07-31
MA46842A (fr) 2019-09-25
US20180134781A1 (en) 2018-05-17
ZA201902608B (en) 2020-07-29
EA201991203A1 (ru) 2019-10-31
JP7133551B2 (ja) 2022-09-08
AU2017363143B2 (en) 2022-07-28
WO2018094112A1 (en) 2018-05-24
KR20190078650A (ko) 2019-07-04
CA3044249A1 (en) 2018-05-24
CN110036029A (zh) 2019-07-19
JP2020500852A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
MX2019005651A (es) Metodos para tratar la obesidad con anticuerpos anti-angptl8.
GEP20237538B (en) Pd-1-binding molecules and methods of use thereof
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2021012134A (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MY195110A (en) Antibodies to PD-1 and uses Thereof
NZ739750A (en) Anti-tigit antibodies and methods of use
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX370720B (es) Anticuerpos anti-gdf15.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
GEP20217317B (en) Combination therapy for the treatment of cancer
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MY173162A (en) Immune balance regulator
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
MX2024004377A (es) Tratamiento mejorado de la dermatitis atopica con tradipitant.
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
SG10201808867PA (en) Anti-nme antibody
PH12018501739A1 (en) Antibodies for il-17c
WO2019112978A3 (en) Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations